Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis in Sharpin-deficient mice

Experimental Dermatology

Volumn 19, Issue 3, 2010, Pages 252-258

  Renninger, Matthew L ^a,d   Seymour, Rosemarie E ^b   Whiteley, Laurence O ^c   Sundberg, John P ^b   HogenEsch, Harm ^a  

^a PURDUE UNIVERSITY   (United States)

^b JACKSON LABORATORY   (United States)

^c PFIZER INC   (United States)

^d Department of Molecular and Anatomical Imaging   (United States)

Author keywords

Antibodies; Atopic dermatitis; Eosinophils; Interleukin 5; Mice

Indexed keywords

AMINE OXIDASE (COPPER CONTAINING); EOTAXIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; MACROPHAGE ELASTASE; MESSENGER RNA; N ACETYLGALACTOSAMINE 4 SULFATASE; STEM CELL FACTOR; TENASCIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1;

ALOPECIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EOSINOPHIL COUNT; EOSINOPHILIA; ERYTHEMA; FEMALE; MOUSE; MOUSE MUTANT; NONHUMAN; PROTEIN EXPRESSION; SKIN ALLERGY; SKINFOLD THICKNESS; TISSUE HOMOGENATE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CYTOKINES; DERMATITIS; EOSINOPHILIA; EOSINOPHILS; FEMALE; INFLAMMATION MEDIATORS; INTERLEUKIN-5; LEUKOCYTE COUNT; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; RATS; RNA, MESSENGER;

EID: 77149121750     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.00944.x     Document Type: Article

References (54)

1. Wardlaw A J, Moqbel R, Kay A B. Eosinophils: biology and role in disease. Adv Immunol 1995, 60:151-266.
2. Rothenberg M E, Hogan S P. The eosinophil. Annu Rev Immunol 2006, 24:147-174.
3. Foster P S, Hogan S P, Ramsay A J, Matthaei K I, Young I G. Interleukin 5 deficiency abolishes eosinophilia, airway hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996, 183:195-201.
4. Justice J P, Borchers M T, Crosby J R. Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology. Am J Physiol Lung Cell Mol Physiol 2003, 284:L169-L178.
5. Humbles A A, Lloyd C M, McMillan S J. A critical role for eosinophils in allergic airways remodeling. Science 2004, 305:1776-1779.
6. Lee J J, Dimina D, Macias M P. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004, 305:1773-1776.
7. Flood-Page P T, Menzies-Gow A N, Kay A B, Robinson D S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003, 167:199-204.
8. Humbles A A, Lu B, Friend D S. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci U S A 2002, 99:1479-1484.
9. Ma W, Bryce P J, Humbles A A. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest 2002, 109:621-628.
10. Leckie M J, ten Brinke A, Khan J. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
11. Kobayashi T, Iijima K, Kita H. Marked Airway eosinophilia prevents development of airway hyper-responsiveness during an allergic response in IL-5 transgenic mice. J Immunol 2003, 170:5756-5763.
12. Bochner B S. Verdict in the case of therapies versus eosinophils: the jury is still out. J Allergy Clin Immunol 2004, 113:3-9.
13. Williams T J. The eosinophil enigma. J Clin Invest 2004, 113:507-509.
14. Leung D Y. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000, 105:860-876.
15. Kiehl P, Falkenberg K, Vogelbruch M, Kapp A. Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol 2001, 145:720-729.
16. Gutermuth J, Ollert M, Ring J, Behrendt H, Jakob T. Mouse models of atopic eczema critically evaluated. Int Arch Allergy Immunol 2004, 135:262-276.
17. Shiohara T, Hayakawa J, Mizukawa Y. Animal models for atopic dermatitis: are they relevant to human disease? J Dermatol Sci 2004, 36:1-9.
18. Schefzyk M, Bruder M, Schmiedl A. Eosinophil granulocytes: functional differences of a new isolation kit compared to the isolation with anti-CD16-conjugated MicroBeads. Exp Dermatol 2009, 18:653-655.
19. HogenEsch H, Gijbels M J J, Offerman E, Van Hooft J, Van Bekkum D W, Zurcher C. A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice. Am J Pathol 1993, 143:972-982.
20. Gijbels M J J, Zurcher C, Kraal G. Pathogenesis of skin lesions in mice with chronic proliferative dermatitis (cpdm/cpdm). Am J Pathol 1996, 148:941-950.
21. Seymour R E, Hasham M G, Cox G A. Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis. Genes Immun 2007, 8:416-421.
22. HogenEsch H, Torregrosa S E, Boggess D, Sundberg B A, Carroll J, Sundberg J P. Increased expression of type 2 cytokines in chronic proliferative dermatitis (cpdm) mutant mice and resolution of inflammation following treatment with IL-12. Eur J Immunol 2001, 31:734-742.
23. Finkelman F D, Madden K B, Cheever A W. Effect of interleukin 12 on immune responses and host protection in mice infected with intestinal nematode parasites. J Exp Med 1994, 179:1563-1572.
24. Bryan S A, O'Connor B J, Matti S. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2149-2153.
25. Yamaguchi Y, Suda T, Suda J. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 1988, 167:43-56.
26. Rothenberg M E, Petersen J, Stevens R L. IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. J Immunol 1989, 143:2311-2316.
27. Stern M, Meagher L, Savill J, Haslett C. Apoptosis in human eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol 1992, 148:3543-3549.
28. Gulbenkian A R, Egan R W, Fernandez X. Interleukin-5 modulates eosinophil accumulation in allergic guinea pig lung. Am Rev Respir Dis 1992, 146:263-266.
29. Mauser P J, Pitman A, Witt A. Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. Am Rev Respir Dis 1993, 148:1623-1627.
30. Van Oosterhout A J, Ladenius A R, Savelkoul H F, Van Ark I, Delsman K C, Nijkamp F P. Effect of anti-IL-5 and IL-5 on airway hyperreactivity and eosinophils in guinea pigs. Am Rev Respir Dis 1993, 147:548-552.
31. Kung T T, Stelts D M, Zurcher J A. Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Am J Respir Cell Mol Biol 1995, 13:360-365.
32. Mauser P J, Pitman A M, Fernandez X. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med 1995, 152:467-472.
33. Buttner C, Lun A, Splettstoesser T, Kunkel G, Renz H. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003, 21:799-803.
34. Flood-Page P, Swenson C, Faiferman I. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007, 176:1062-1071.
35. Stein M L, Collins M H, Villanueva J M. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006, 118:1312-1319.
36. Oldhoff J M, Darsow U, Werfel T. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005, 60:693-696.
37. Phipps S, Flood-Page P, Menzies-Gow A, Ong Y E, Kay A B. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 2004, 122:1406-1412.
38. Flood-Page P, Menzies-Gow A, Phipps S. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003, 112:1029-1036.
39. Kopf M, Brombacher F, Hodgkin P D. IL-5-deficient mice have a developmental defect in CD5 + B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996, 4:15-24.
40. Livak K J, Schmittgen T D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
41. Simon D, Braathen L R, Simon H U. Anti-interleukin-5 antibody therapy in eosinophilic diseases. Pathobiology 2005, 72:287-292.
42. Grimaldi J C, Yu N X, Grunig G. Depletion of eosinophils in mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3). J Leukoc Biol 1999, 65:846-853.
43. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958, 18:853-856.
44. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.
45. Wasserman S I, Austen K F. Arylsulfatase B of human lung. Isolation, characterization, and interaction with slow-reacting substance of anaphylaxis. J Clin Invest 1976, 57:738-744.
46. Herman J J. Eosinophil diamine oxidase activity in acute inflammation in humans. Agents Actions 1982, 12:46-48.
47. Cho J Y, Miller M, Baek K J. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest 2004, 113:551-560.
48. Pretolani M. IL-10:A potential therapy for allergic inflammation? Immunol Today 1997, 18:277-280.
49. Dunstan J A, Hale J, Breckler L. Atopic dermatitis in young children is associated with impaired interleukin-10 and interferon-gamma responses to allergens, vaccines and colonizing skin and gut bacteria. Clin Exp Allergy 2005, 35:1309-1317.
50. Seneviratne S L, Jones L, Bailey A S, Black A P, Ogg G S. Severe atopic dermatitis is associated with a reduced frequency of IL-10 producing allergen-specific CD4 + T cells. Clin Exp Dermatol 2006, 31:689-694.
51. Kay A B, Phipps S, Robinson D S. A role for eosinophils in airway remodelling in asthma. Trends Immunol 2004, 25:477-482.
52. Wu L, Fan J, Matsumoto S, Watanabe T. Induction and regulation of matrix metalloproteinase-12 by cytokines and CD40 signaling in monocyte/macrophages. Biochem Biophys Res Commun 2000, 269:808-815.
53. Ala-Aho R, Johansson N, Grenman R, Fusenig N E, Lopez-Otin C, Kahari V M. Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1. Oncogene 2000, 19:248-257.
54. Di G N, Indoh I, Jackson N. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration. J Immunol 2006, 177:2638-2650.